375 related articles for article (PubMed ID: 32842985)
1. Effects of ∆
Raymundi AM; da Silva TR; Sohn JMB; Bertoglio LJ; Stern CA
BMC Psychiatry; 2020 Aug; 20(1):420. PubMed ID: 32842985
[TBL] [Abstract][Full Text] [Related]
2. Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.
Stern CA; Gazarini L; Vanvossen AC; Zuardi AW; Galve-Roperh I; Guimaraes FS; Takahashi RN; Bertoglio LJ
Eur Neuropsychopharmacol; 2015 Jun; 25(6):958-65. PubMed ID: 25799920
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol and the Remainder of the Plant Extract Modulate the Effects of Δ9-Tetrahydrocannabinol on Fear Memory Reconsolidation.
Murkar A; Kent P; Cayer C; James J; Durst T; Merali Z
Front Behav Neurosci; 2019; 13():174. PubMed ID: 31417379
[No Abstract] [Full Text] [Related]
4. Impact of cannabidiol-rich hemp extract oil on reconsolidation disruption of naturalistic interoceptive aversive memory in humans: Protocol for a randomized clinical trial.
Zaizar ED; Papini S; O'Connor P; Telch MJ
Contemp Clin Trials; 2022 Aug; 119():106847. PubMed ID: 35811050
[TBL] [Abstract][Full Text] [Related]
5. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
6. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties.
Sharpe L; Sinclair J; Kramer A; de Manincor M; Sarris J
J Transl Med; 2020 Oct; 18(1):374. PubMed ID: 33008420
[TBL] [Abstract][Full Text] [Related]
7. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
8. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
[TBL] [Abstract][Full Text] [Related]
9. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
Stanciu CN; Brunette MF; Teja N; Budney AJ
Psychiatr Serv; 2021 Apr; 72(4):429-436. PubMed ID: 33530732
[TBL] [Abstract][Full Text] [Related]
10. Use of cannabinoids for the treatment of patients with post-traumatic stress disorder.
Forsythe ML; Boileau AJ
J Basic Clin Physiol Pharmacol; 2021 Mar; 33(2):121-132. PubMed ID: 33662194
[TBL] [Abstract][Full Text] [Related]
11. Female but not male rats show biphasic effects of low doses of Δ
Salviato BZ; Raymundi AM; Rodrigues da Silva T; Salemme BW; Batista Sohn JM; Araújo FS; Guimarães FS; Bertoglio LJ; Stern CA
Neuropharmacology; 2021 Sep; 196():108684. PubMed ID: 34181978
[TBL] [Abstract][Full Text] [Related]
12. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
13. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.
Morgan CJA; Freeman TP; Hindocha C; Schafer G; Gardner C; Curran HV
Transl Psychiatry; 2018 Sep; 8(1):181. PubMed ID: 30185793
[TBL] [Abstract][Full Text] [Related]
14. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
15. Interactions between cannabidiol and Δ
Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
[TBL] [Abstract][Full Text] [Related]
16. Effect of prior foot shock stress and Δ
Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.
Bitencourt RM; Takahashi RN
Front Neurosci; 2018; 12():502. PubMed ID: 30087591
[TBL] [Abstract][Full Text] [Related]
18. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
